Summit Therapeutics Ownership | Who Owns Summit Therapeutics?


OverviewForecastFinancialsChartTranscripts

Summit Therapeutics Ownership Summary


Summit Therapeutics is owned by 2.73% institutional investors, 86.05% insiders, and 11.22% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 4.54% of SMMT shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 0.46% of its assets in Summit Therapeutics shares.

SMMT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSummit Therapeutics2.73%86.05%11.22%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Baker bros. advisors lp33.72M4.54%$696.72M
Vanguard group11.38M1.53%$235.11M
Fmr8.92M1.20%$184.24M
Blackrock7.90M1.13%$61.61M
Blackrock funding, inc. /de7.36M0.99%$152.14M
State street6.36M0.86%$131.44M
Price t rowe associates inc /md/4.54M0.61%$93.77M
Geode capital management3.13M0.42%$64.74M
Pictet asset management sa2.16M0.29%$45.55M
Morgan stanley1.93M0.26%$39.81M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Apeiron capital1.31M12.87%$27.08M
Baker bros. advisors lp33.72M5.03%$696.72M
Superstring capital management lp197.25K4.01%$4.08M
Capricorn fund managers496.27K3.44%$10.25M
Cutter capital management, lp400.00K3.36%$7.72M
Polymer capital management (hk)817.28K2.33%$16.88M
Sectoral asset management74.07K0.94%$1.53M
Rock springs capital management lp710.00K0.86%$14.67M
Healthinvest partners ab92.74K0.75%$203.40K
Polianta74.70K0.64%$1.54M

Top Buyers

HolderShares% AssetsChange
Vanguard group11.38M0.00%2.71M
State street6.36M0.00%2.34M
Morgan stanley1.93M0.00%1.28M
Price t rowe associates inc /md/4.54M0.01%633.67K
Blackrock funding, inc. /de7.36M0.00%517.13K

Top Sellers

HolderShares% AssetsChange
Blackrock7.90M0.00%-1.92M
Balyasny asset management---1.70M
Millennium management887.01K0.01%-1.16M
Darwin global management---1.08M
Anson funds management lp---941.91K

New Positions

HolderShares% AssetsChangeValue
Capricorn fund managers496.27K3.44%496.27K$10.25M
Cutter capital management, lp400.00K3.36%400.00K$7.72M
Tudor investment corp et al347.24K0.01%347.24K$7.17M
First trust advisors lp171.52K0.00%171.52K$3.54M
Simplex trading114.65K0.00%114.65K$894.00K

Sold Out

HolderChange
Citadel advisors-5.00
Geowealth management-14.00
Stephens consulting-20.00
Rialto wealth management-20.00
Capital performance advisors llp-36.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2025101-58.09%20,268,240-79.02%21.61%47-63.85%28-59.42%
Jun 30, 20252488.30%97,673,633-0.07%137.50%13317.70%70-4.11%
Mar 31, 202514-93.83%26,286,219-71.60%32.20%7-95.17%2-94.74%
Dec 31, 20242089.47%86,084,9161.94%118.77%13112.93%3911.43%
Sep 30, 202418943.18%84,448,62517.02%1111.18%11579.69%35-23.91%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF3.43M0.46%-167.64K
T. Rowe Price Health Sciences3.11M0.42%365.22K
Fidelity Growth Compy Commingled Pl S2.72M0.37%26.86K
SPDR® S&P Biotech ETF2.43M0.33%5.41K
Vanguard Total Stock Mkt Idx Inv2.37M0.32%-50.74K
iShares Russell 2000 ETF2.31M0.31%-
Fidelity Growth Company Fund2.09M0.28%6.27K
Vanguard Small Cap Index1.80M0.24%-12.15K
Fidelity Select Biotechnology1.63M0.22%-55.10K
Vanguard Institutional Extnd Mkt Idx Tr1.52M0.20%-660.32K

Recent Insider Transactions


DateNameRoleActivityValue
Oct 21, 2025Xia Yu-Buy$10.00M
Oct 21, 2025DUGGAN ROBERT W Co-Chief Executive OfficerBuy$499.98K
Oct 21, 2025Zanganeh Mahkam Co-Chief Executive OfficerBuy$499.98K
Sep 11, 2025Zanganeh Mahkam Co-Chief Executive OfficerBuy$90.35K
Sep 10, 2025Zanganeh Mahkam Co-Chief Executive OfficerBuy$5.89M

Insider Transactions Trends


DateBuySell
2025 Q43-
2025 Q34-
2025 Q2--
2025 Q1--
2024 Q4--

SMMT Ownership FAQ


Who Owns Summit Therapeutics?

Summit Therapeutics shareholders are primarily institutional investors at 2.73%, followed by 86.05% insiders and 11.22% retail investors. The average institutional ownership in Summit Therapeutics's industry, Biotech Stocks , is 45.22%, which Summit Therapeutics falls below.

Who owns the most shares of Summit Therapeutics?

Summit Therapeutics’s largest shareholders are Baker bros. advisors lp (33.72M shares, 4.54%), Vanguard group (11.38M shares, 1.53%), and Fmr (8.92M shares, 1.20%). Together, they hold 7.27% of Summit Therapeutics’s total shares outstanding.

Does Blackrock own Summit Therapeutics?

Yes, BlackRock owns 1.13% of Summit Therapeutics, totaling 7.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 61.61M$. In the last quarter, BlackRock decreased its holdings by -1.925M shares, a -19.59% change.

Who is Summit Therapeutics’s biggest shareholder by percentage of total assets invested?

Apeiron capital is Summit Therapeutics’s biggest shareholder by percentage of total assets invested, with 12.87% of its assets in 1.31M Summit Therapeutics shares, valued at 27.08M$.

Who is the top mutual fund holder of Summit Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Summit Therapeutics shares, with 0.46% of its total shares outstanding invested in 3.43M Summit Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools